• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Liver Meeting 2018: 3 Hep C Study Highlights


Find out: why HCV-infected hearts can be viable for non-infected recipients; why screening pregnant women for HCV is worth it; and, how even injection drug users can achieve SVR.

Following are highlights from 3 important studies presented at The Liver Meeting® 2018, held Nov. 9-13 in San Francisco by the American Association for the Study of Liver Diseases (AASLD). The studies cover key current issues surrounding hepatitis C screening and treatment. Investigators reported that: Universal (vs risk-based) screening of pregnant women at risk for HCV infection is a more efficient and cost-effective diagnostic approach Injection drug users who are infected with HCV have high rates of treatment adherence and relatively high rates of sustained virologic response In HCV-negative cardiac transplant patients who receive HCV-infected donor hearts, pre-emptive treatment with DAA therapy prevents chronic HCV infectionAll The Liver Meeting 2018 abstracts are published in the Oct 1 2018 issue of Hepatology.

© 2024 MJH Life Sciences

All rights reserved.